DEALS: Isis, Alnylam form RNAi company

Isis, Alnylam form RNAi company








$202 licensing deal

Alpharma has agreed to pay Germany's IDEA up to $202 million in upfront fees and milestones for the U.S. rights to the late-stage pain drug Diractin, a prescription topical NSAID.

Nabi Biopharmaceuticals


$185M sale

Nabi Biopharmaceuticals plans to sell its biologics unit to Germany's Biotest for $185 million.

Boehringer Ingelheim


$103.5M partnership

Boehringer has signed a second agreement with Ablynx to develop and commercialize up to 10 different Nanobody therapeutics.


Azimuth Opportunity

$100M stock deal

VC firm Azimuth Opportunity will purchase $100 million of Medivation's stock over the next 18 months as the drug developer pushes through a late-stage trial of an experimental Alzheimer's drug.


BioDelivery Sciences

$90M licensing deal

Meda will pay BioDelivery up to $90 million in exchange for a licensing deal covering the North American rights to BEMA Fentanyl, a new pain patch for cancer patients.

Ventana Medical Systems

Spring BioScience

$31M acquisition

Ventana Medical Systems has inked a deal to acquire Spring BioScience, which makes rabbit monoclonal antibodies and other reagents.

Isis Pharmaceuticals

Alnylam Pharmaceuticals

Company formation

Isis and Alnylam have teamed up to form Regulus Therapeutics, a company that will focus on developing new drugs based on micro-RNA.


Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.